Sodium thiosulfate prevents cisplatin-induced hypomagnesemia

Clearance studies were performed in four groups of male Wistar rats to assess the protective effect of sodium thiosulfate on cisplatin-induced hypomagnesemia. In group I, sodium thiosulfate (400 mg/kg) was injected intraperitoneally once weekly for 3 consecutive weeks. In group II, only cisplatin (2.5 mg/kg) was administered. In group III, both cisplatin (2.5 mg/kg) and sodium thiosulfate (400 mg/kg) were injected via the intraperitoneal route. When both drugs were administered together, they were injected into different parts of the peritoneal cavity. In group IV cisplatin was administered intraperitoneally and sodium thiosulfate intravenously. Sodium thiosulfate prevented a rise in plasma creatinine. The overall glomerular filtration rates of groups III and IV were the same as in group I. Hypomagnesemia was noted in group II, whereas in groups I, III, and IV the plasma magnesium level remained unchanged. The fractional excretion of magnesium was also higher in group II than in groups I, III, and IV. These differences persisted for the duration of the study. These results suggest that concurrent injections of sodium thiosulfate intraperitoneally or intravenously prevented the hypomagnesemic and the nephrotoxic effects of cisplatin and can be of clinical significance.